About Human Longevity, Inc.
Human Longevity, Inc. (HLI) is the genomics-based, technology-driven company creating the world’s largest and most comprehensive database of whole genome, phenotype and clinical data. HLI is developing and applying large scale computing and machine learning to make novel discoveries to revolutionize the practice of medicine. HLI’s business also includes the HLI Health Nucleus, a genomic powered clinical research program which uses whole genome sequence analysis, advanced clinical imaging and innovative machine learning, along with curated personal health information, to deliver the most complete picture of individual health.
The company has completed an offering of Series B Preferred Stock, raising in excess of $220 million. HLI previously raised $80 million in its Series A offering which closed in Summer 2014. Our investors are a diverse group of individuals and companies who share our common goal and passion of changing healthcare, tackling the diseases of aging, and extending the healthy human lifespan.